Dacomitinib: First Global Approval
- 57 Downloads
Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours. In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan. This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): non-small cell lung cancer (version 1.2019). 2018. http://www.nccn.org. Accessed 07 Oct 2018.
- 4.US FDA. Vizimpro® (dacomitinib) tablets: US prescribing information. 2018. http://www.fda.gov. Accessed 07 Oct 2018.
- 5.Pfizer. U.S. FDA approves Vizimpro® (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer [media release]. 2018. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer. Accessed 07 Oct 2018.
- 6.Pfizer. U.S. FDA and European Medicines Agency accept regulatory submissions for review of dacomitinib to treat metastatic non-small cell lung cancer with EGFR-activating mutations [media release]. 2018. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_dacomitinib_to_treat_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations. Accessed 07 Oct 2018.
- 7.SFJ Pharmaceuticals. The SFJ Pharmaceuticals Group announces agreement with Pfizer to co-develop dacomitinib as first-line treatment for patients with advanced non-small cell lung cancer [media release]. 2012. https://www.prnewswire.com/news-releases/the-sfj-pharmaceuticals-group-announces-agreement-with-pfizer-to-co-develop-dacomitinib-as-first-line-treatment-for-patients-with-advanced-non-small-cell-lung-cancer-168896716.html. Accessed 07 Oct 2018.
- 14.Ruiz-Garcia A, Masters JC, Mendes da Costa L, et al. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol. 2016;56(2):223–30.Google Scholar
- 21.Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014;15(12):1379–88.Google Scholar
- 22.Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(27):3337–44.CrossRefGoogle Scholar
- 25.Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145–54.CrossRefGoogle Scholar
- 31.Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 2018;121(3):348–56.CrossRefGoogle Scholar
- 34.Qiagen. QIAGEN receives FDA approval to expand use of EGFR test in lung cancer [media release]. 2018. http://corporate.qiagen.com/newsroom/press-releases/2018/20180928_fda_egfr. Accessed 07 Oct 2018.